US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NervGen Pharma Corp.

5.84

0.0000

Volume:- -

Turnover:- -

Market Cap:464.83M

PE:- -

High:5.84

Open:5.84

Low:5.84

Close:5.84

52wk High:6.10

52wk Low:1.50

Shares:79.59M

Float Shares:66.49M

Volume Ratio:0.58

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.2734

ROE:-820.11%

ROA:-88.77%

PB:-215.17

PE(LYR):-21.36

Loading ...

Overview Company News Filings

Company Profile

Company Name:

NervGen Pharma Corp.

Exchange:

OTCQB

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

https://www.nervgen.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NGENF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NGENF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGENF\",,,,,undefined,":{"symbol":"NGENF","market":"US","secType":"STK","nameCN":"NervGen Pharma Corp.","latestPrice":5.84,"timestamp":1770930000000,"preClose":5.84,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":66489329,"shares":79593757,"eps":0,"marketStatus":"Pre-Mkt","change":0,"latestTime":"02-12 16:00:00 EST Delay","open":5.84,"high":5.84,"low":5.84,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770993000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":5.84,"volumeRatio":0.5788426462236993},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGENF\",,,,,undefined,":{"symbol":"NGENF","floatShares":66489329,"roa":"-88.77%","roe":"-820.11%","lyrEps":-0.273387,"volumeRatio":0.5788426462236993,"shares":79593757,"dividePrice":0,"high":5.84,"amplitude":0,"preClose":5.84,"low":5.84,"week52Low":1.5,"pbRate":"-215.17","week52High":6.1,"institutionHeld":0,"latestPrice":5.84,"eps":0,"divideRate":0,"volume":0,"delay":15,"open":5.84,"prevYearClose":5.6,"prevWeekClose":5.84,"prevMonthClose":5.84,"prevQuarterClose":5.6,"fiveDayClose":5.84,"twentyDayClose":5.84,"sixtyDayClose":2.36},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGENF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-08","symbol":"NGENF","oldSymbol":"NGENF","defaultRemindTime":1767882600000,"newSymbol":"NGEN","exchange":"OTCQB","type":"symbolChange","dateTimestamp":1767848400000},{"market":"US","date":"2024-11-14","symbol":"NGENF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-08-22","symbol":"NGENF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1724299200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-16","symbol":"NGENF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715832000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-11-14","symbol":"NGENF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1668402000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGENF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGENF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1750050000000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"https://www.nervgen.com","stockEarnings":[{"period":"1week","weight":-0.0917},{"period":"1month","weight":-0.0748},{"period":"3month","weight":-0.1162},{"period":"6month","weight":-0.1722},{"period":"ytd","weight":-0.1722}],"description":"NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.","exchange":"OTCQB","name":"NervGen Pharma Corp.","nameEN":"NervGen Pharma Corp."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NGENF\",market:\"US\",,,undefined,":null}}